Wall Street Bullish on Soleno Therapeutics Ahead of Key FDA Decision

Soleno Therapeut. US8342033094

While shares of Soleno Therapeutics saw minimal movement in Friday’s trading session, closing with a slight decline, this surface-level calm belies a significant surge of confidence emanating from Wall Street. Multiple market analysts are highlighting substantial potential in the biotechnology firm, pointing to a major upcoming regulatory catalyst.

The company’s primary focus is developing therapies for rare diseases. Its most closely watched program is the drug candidate DCCR for Prader-Willi syndrome, a condition that currently lacks any approved pharmacological treatments.